PA
CAPR icon

Parallel Advisors’s Capricor Therapeutics CAPR Stock Holding History

Parallel Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95K Sell
247
-34
-12% -$1.03K ﹤0.01% 3154
2026
Q1 		$8.54K Buy
281
+34
+14% +$906 ﹤0.01% 2822
2025
Q4 		$7.13K Buy
+247
New +$3.23K ﹤0.01% 2736
2025
Q2 		– Sell
-13
Closed -$123 – 3565
2025
Q1 		$123 Hold
13
– – ﹤0.01% 3427
2024
Q4 		$179 Buy
+13
New +$228 ﹤0.01% 3394

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Parallel Advisors's CAPR Position: Q2 2026 in Review

Parallel Advisors reduced its Capricor Therapeutics (CAPR) stake by 12% in Q2 2026, selling an estimated $1.03K and leaving 247 shares worth $5.95K. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

Parallel Advisors first reported a position in CAPR in Q4 2024 and has held it in 5 quarters since. The position peaked at $8.54K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Parallel Advisors held 247 shares of Capricor Therapeutics worth $5.95K as of Q2 2026.
  • Parallel Advisors sold 34 Capricor Therapeutics shares in Q2 2026, an estimated $1.03K.
  • Capricor Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3154 holding.
  • Parallel Advisors first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Parallel Advisors's Capricor Therapeutics position peaked at $8.54K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.